Regulus Adds Liver and Kidney Drugs to Its Pipeline
When you’re trading stocks online, remember to watch out for new products in the pipeline of manufacturers. If the potential behind these soon-to-be-launched products is great, it would significantly raise the stock value of the companies. That holds true for the pharmaceutical sector as well.
Regulus Therapeutics ($RGLS) now has two new drugs that must be tested for treatment of kidney and liver diseases. Human clinical trials for the drugs will start in 2017.
RGLS5040 for PBC Liver Disease
RGLS5040 has been created for treating cholestatic diseases such as primary biliary cholangitis (PBC) and primary sclerosis cholangitis as well as congenital diseases such as Alagille syndrome. Cholestatic diseases can seriously damage the liver by blocking bile flow from the liver. Bile secreted by the liver gets stored in the gall bladder and reaches the small intestine through bile ducts. In the small intestine, the bile aids in the digestion process. PBC causes the liver’s bile ducts to get damaged progressively, resulting in the bile not being transmitted to the small intestines well. This causes the bile to build up in the liver resulting in the liver tissues getting inflamed and scarred. If left unchecked, this damage to liver tissues can eventually cause a breakdown in liver functions.
RGLS5040 is therefore a very important drug. And there isn’t much competition to it as well. Currently, Ocaliva by Intercept Pharmaceuticals’ ($ICPT) is the only drug approved for PBC in the United States. RGLS5040 can be used as part of a combination therapy or as a monotherapy.
RGLS4326 for ADPKD Kidney Disease
RGLS4326 is the other candidate by Regulus, and targets autosomal dominant polycystic kidney (ADPKD) disease. This condition causes the development of cysts or fluid-filled pockets in the kidneys, which impairs their function. This condition has been known to affect 12.5 million individuals worldwide, with no therapy approved in the US. That presents a major opportunity for $RGLS, with the Samsca drug by Otsuka Pharmaceuticals only approved for ADPKD in the EU, Canada and Japan.
If these drugs get through the clinical trials stage successfully they will offer a new income opportunity for Regulus and expand its pipeline to five products, with the other candidates being RG-101 for hepatitis C that the FDA has kept under clinical hold, the Alport syndrome candidate RG-012 developed in partnership with Genzyme, the Sanofi’s group company ($SNY), and the RG-125 NASH candidate that is in the process of development with AstraZeneca PLC ($AZN).
Pharmaceutical companies count on these launches and successful trials to raise their income potential and stock value. To keep tabs on their market efforts, you need competitive trading platforms in online stock trading. TradeZero offers these and more. Get in touch with us at +1 954-944-3885, or email us at email@example.com.
The content provided here is solely for informational and educational purposes and does not constitute an offer to sell or a solicitation to buy any security or instrument which may be referenced upon the site, or an offer to provide advisory or other services by TradeZero in any jurisdiction in which such offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction. Investors are advised not to rely on the information contained in this writing to make an informed investment or financial decision. TradeZero explicitly disclaims all liability for any action taken based on any information contained in this writing.